Skip to main content

In Memoriam: David J. Galas, Ph.D. (1944-2023) >>

About Us
Grants
Startup Investments
- Investing in Washington
- Active Portfolio & Exits
Stories
News
- Articles
- Videos
- Reports
Contact

Keywords:

Juno stock spikes after cancer drug trial shows 91 percent remission rate

Post navigation

← How do you make surgery safer? This Seattle startup has a plan and $2.5M to make it work Juno stock pops 15 percent after $44M acquisition of Boston-area biotech →

Comments are closed.

Home
Contact

About Us

Grants

Startup Investments
- Investing in Washington
- Active Portfolio & Exits
In Memoriam: David J. Galas, Ph.D. (1944-2023)

News
- Articles
- Videos
- Stories

LinkedIn
Twitter

Washington Research Foundation values diversity. We’re committed to diversity, equity and inclusion in our staff, our board of directors, and the researchers, entrepreneurs and organizations we fund. We encourage people of color, women and other underserved communities to apply for our employment, grant-making and investment opportunities.

© 2023 Washington Research Foundation, Seattle WA

Terms of Use
Privacy Policy
(206) 336-5600
Site by The Medium

About Us
Grants
Startup Investments
- Investing in Washington
- Active Portfolio & Exits
Stories
News
- Articles
- Videos
- Reports
Contact